Monotropein Protects against Inflammatory Bone Loss and Suppresses Osteoclast Formation and Bone Resorption by Inhibiting NFATc1 via NF-κB and Akt/GSK-3β Pathway

• Published in: Nutrients Vol. 14; no. 19; p. 3978
• Main Authors: Zhang, Qi, Hu, Sijing, He, Yuqiong, Song, Zile, Shen, Yi, Zhao, Zihui, Zhang, Quanlong, Qin, Luping, Zhang, Qiaoyan
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 24.09.2022; MDPI
• Subjects: Acid phosphatase; Acid phosphatase (tartrate-resistant); Acid resistance; Actin; AKT protein; Akt/GSK3β pathway; Animal tissues; Antibodies; Arthritis; Biomarkers; Bone growth; Bone loss; Bone marrow; Bone mineral content; Bone resorption; c-Fos protein; Cathepsin K; Cathepsins; Chronic obstructive pulmonary disease; Computer architecture; Cytokines; Ethylenediaminetetraacetic acid; Gelatinase B; Glycogen; Glycogen synthase kinase 3; Glycogens; Herbal medicine; Inflammation; inflammatory bone loss; Inflammatory diseases; Interleukin 6; Kinases; Laboratory animals; Ligands; Lipopolysaccharides; Macrophages; Matrix metalloproteinase; Matrix metalloproteinases; Medicinal plants; Medicine, Botanic; Medicine, Herbal; Metabolites; Metalloproteinase; monotropein; Muscle proteins; NF-κB protein; NFATc1; Nuclear transport; osteoclast; Osteoclastogenesis; Osteoclasts; Osteoporosis; Phosphatase; Phosphatases; Phosphorylation; Protein kinases; Proteins; Rankings; Synthesis; Translocation; Tumor necrosis factor-TNF; China; Pittsburgh Pennsylvania; United Kingdom > UK; United States > US
• ISSN: 2072-6643; 2072-6643
• DOI: 10.3390/nu14193978

Monotropein (Mon) is a kind of iridoid glycoside plant secondary metabolite primarily present in some edible and medicinal plants. The aim of this study was to investigate the effect of Mon on lipopolysaccharide (LPS)-induced inflammatory bone loss in mice and osteoclasts (OCs) derived from bone marrow-derived macrophages (BMMs), and explore the mechanisms underlying the effect of Mon on LPS-induced osteoclastogenesis. It was found that Mon markedly attenuated deterioration of the bone micro-architecture, enhanced tissue mineral content (TMC) and bone volume/total volume (BV/TV), reduced structure model index (SMI) and trabecular separation/spacing (Tb.Sp) in the bone tissue and decreased the activities of tartrate resistant acid phosphatase-5b (TRACP-5b), receptor activator NF-κB (RANK), and receptor activator NF-κB ligand (RANKL) as well as the serum levels of interleukin 6 (IL-6) and interleukin 1β (IL-1β) in LPS-treated mice. In addition, Mon treatment reduced the number of TRAP positive OCs in the bone tissue of LPS-treated mice and also exerted a stronger inhibitory effect on formation, differentiation, and F-actin ring construction of OCs derived from BMMs. Mon significantly inhibited the expression of the nuclear factor of activated T-cells c1 (NFATc1) and the immediate early gene (C-Fos) and nuclear translocation of NFATc1 in LPS-treated OCs, thereby inhibiting the expression of matrix metalloproteinase-9 (MMP-9), cathepsin K (CtsK), and TRAP. Mon significantly inhibited the expression of TRAF6, phosphorylation of P65, and degradation of IKBα, thus inhibiting the activation of NF-κB pathway in LPS-induced inflammatory mice and OCs derived from BMMs, and also inhibited LPS-induced phosphorylation of protein kinase B (Akt) and Glycogen synthase kinase 3β (GSK-3β) in OCs derived from BMMs. In conclusion, these results suggested that Mon could effectively inhibit osteoclastogenesis both in vitro and in vivo and therefore may prove to be potential option for prevention and treatment of osteoclastic bone resorption-related diseases.